Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs

Posted inBiotechnology

Attovia Therapeutics, Braveheart Bio and Vogenx have set target ranges for their IPOs, positioning the trio to collectively net more than $500 million from public investors.